High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 3, 2017, Pages

  Lenhard, Justin R ^a,b   Smith, Nicholas M ^a   Bulman, Zackery P ^a   Tao, Xun ^c   Thamlikitkul, Visanu ^d   Shin, Beom S ^e   Nation, Roger L ^f   Li, Jian ^f   Bulitta, Jürgen B ^c   Tsuji, Brian T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

^e Catholic University of Daegu   (South Korea)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Acinetobacter; Antibiotic resistance; Antimicrobial combinations; Meropenem; Polymyxins; Sulbactam; Synergism

Indexed keywords

MEROPENEM; POLYMYXIN B; SULTAMICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; DRUG COMBINATION; SULBACTAM; THIENAMYCIN DERIVATIVE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BACTERIUM ISOLATION; DRUG HALF LIFE; DRUG MEGADOSE; HOLLOW FIBER INFECTION MODEL; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MODEL; POLYMYXIN RESISTANT ACINETOBACTER BAUMANNII; PRIORITY JOURNAL; ACINETOBACTER INFECTIONS; AREA UNDER THE CURVE; BIOAVAILABILITY; BLOOD; BODY MASS; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; STATISTICAL MODEL;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMPICILLIN; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BODY MASS INDEX; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; POLYMYXIN B; SULBACTAM; THIENAMYCINS;

EID: 85014072479     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01268-16     Document Type: Article

References (21)

1. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. https://doi.org/10.1128/CMR.00058-07.
2. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K, Rayner CR, Paterson D. 2006. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:589-601. https://doi.org/10.1016/S1473-3099(06)70580-1.
3. Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. 2016. Agents of last resort: polymyxin resistance. Infect Dis Clin North Am 30:391-414. https://doi.org/10.1016/j.idc.2016.02.005.
4. Gottig S, Gruber TM, Higgins PG, Wachsmuth M, Seifert H, Kempf VA. 2014. Detection of pan drug-resistant Acinetobacter baumannii in Germany. J Antimicrob Chemother 69:2578-2579. https://doi.org/10.1093/jac/dku170.
5. Tekce AY, Erbay A, Cabadak H, Yagci S, Karabiber N, Sen S. 2011. Pan-resistant Acinetobacter baumannii mediastinitis treated successfully with tigecycline: a case report. Surg Infect (Larchmt) 12:141-143. https://doi.org/10.1089/sur.2009.063.
6. Lin GM, Lin JC, Chen PJ, Siu LK, Huang LY, Chang FY. 2008. Pan-drug resistant Acinetobacter baumannii bacteremia following endoscopic retrograde cholangiopancreatography. Am J Gastroenterol 103:498-499. https://doi.org/10.1111/j.1572-0241.2007.01646-17.x.
7. Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. 2007. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 39:38-43. https://doi.org/10.1080/00365540600951184.
8. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE. 2008. Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56:432-436. https://doi.org/10.1016/j.jinf.2008.04.002.
9. Qureshi ZA, Hittle LE, O'Hara JA, Rivera JI, Syed A, Shields RK, Pasculle AW, Ernst RK, Doi Y. 2015. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60:1295-1303. https://doi.org/10.1093/cid/civ048.
10. Tsuji BT, von Eiff C, Kelchlin PA, Forrest A, Smith PF. 2008. Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother 52:1533-1537. https://doi.org/10.1128/AAC.01254-07.
11. Lenhard JR, Bulitta JB, Connell TD, King-Lyons N, Landersdorfer CB, Cheah SE, Thamlikitkul V, Shin BS, Rao G, Holden PN, Walsh TJ, Forrest A, Nation RL, Li J, Tsuji BT. 2017. High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii. J Antimicrob Chemother 72:153-165. https://doi.org/10.1093/jac/dkw355.
12. AstraZeneca Pharmaceuticals. 2013. Merrem package insert. Astra- Zeneca Pharmaceuticals, Wilmington, DE.
13. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Bordinhao RC, Wang J, Forrest A, Nation RL, Li J, Zavascki AP. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. https://doi.org/10.1093/cid/cit334.
14. Zusman O, Avni T, Leibovici L, Adler A, Friberg L, Stergiopoulou T, Carmeli Y, Paul M. 2013. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:5104-5111. https://doi.org/10.1128/AAC.01230-13.
15. Lenhard JR, Brown T, Rybak MJ, Meaney CJ, Norgard NB, Bulman ZP, Brazeau DA, Gill SR, Tsuji BT. 2015. Sequential evolution of vancomycinintermediate resistance alters virulence in Staphylococcus aureus: pharmacokinetic/pharmacodynamic targets for vancomycin exposure. Antimicrob Agents Chemother 60:1584-1591. https://doi.org/10.1128/AAC.02657-15.
16. Pfizer, Inc. 2014. Unasyn package insert. Pfizer, Inc., New York, NY.
17. Tsuji BT, Landersdorfer CB, Lenhard J, Cheah SE, Thamlikitkul V, Rao GG, Holden PN, Forrest A, Bulitta JB, Nation RL, Li J. 2016. The paradoxical effect of polymyxin B: high drug exposure amplifies resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 60:3913-3920. https://doi.org/10.1128/aac.02831-15.
18. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J Antimicrob Chemother 15(Suppl A):125-130.
19. Cheah SE, Bulitta JB, Li J, Nation RL. 2014. Development and validation of a liquid chromatography-mass spectrometry assay for polymyxin B in bacterial growth media. J Pharm Biomed Anal 92:177-182. https://doi.org/10.1016/j.jpba.2014.01.015.
20. Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA. 2015. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother 59:1680-1689. https://doi.org/10.1128/AAC.04808-14.
21. Yokoyama Y, Matsumoto K, Ikawa K, Watanabe E, Shigemi A, Umezaki Y, Nakamura K, Ueno K, Morikawa N, Takeda Y. 2014. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models. Int J Antimicrob Agents 43:547-552. https://doi.org/10.1016/j.ijantimicag.2014.02.012.